--- title: "ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low" type: "News" locale: "en" url: "https://longbridge.com/en/news/301066580.md" description: "ArriVent BioPharma (NASDAQ:AVBP) shares plummeted 49% to a 52-week low after its Phase 3 FURVENT trial for firmonertinib missed the primary endpoint of progression-free survival in non-squamous NSCLC patients with EGFR exon 20 insertion mutations. Despite this, the drug showed secondary benefits, including improved objective response rates and a favorable safety profile compared to controls." datetime: "2026-10-06T18:09:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/301066580.md) - [en](https://longbridge.com/en/news/301066580.md) - [zh-HK](https://longbridge.com/zh-HK/news/301066580.md) generator: "portal-rs" --- # ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low **ArriVent BioPharma Inc.** (NASDAQ:AVBP) stock fell on Tuesday with a session volume of 14.10 million compared to the average volume of 524.163 thousand, according to Benzinga Pro data. The company announced that its Phase 3 FURVENT trial evaluating firmonertinib failed to achieve its primary endpoint. The clinical-stage biopharmaceutical company tested the drug as a standalone therapy for patients suffering from previously untreated, locally advanced, or metastatic non-squamous non-small cell lung cancer. Specifically, the study targeted patients harboring EGFR exon 20 insertion mutations. Ultimately, the trial missed the primary progression-free survival target. ## Secondary Endpoints Show Clinical Benefit Despite missing the principal metric, firmonertinib demonstrated clinical advantages across secondary endpoints. Evaluators recorded noticeable improvements in progression-free survival based on direct investigator assessments. Furthermore, the blinded independent central review confirmed a strong objective response rate for the experimental therapy. While the data require further maturation, researchers observed an encouraging trend toward enhanced overall survival among treated patients. **Read Also: Merck, Daiichi Sankyo Scrap FDA Application for Lung Cancer Drug** ## Detailed FURVENT Trial Efficacy Data Patients receiving the 240mg dose of firmonertinib posted a median progression-free survival of 11.0 months by blinded review, narrowly edging out the 9.5 months observed in the control group. The lower 160mg dose yielded an 8.4-month median. Under investigator assessment, the data showed clearer separation. The 240mg dose achieved an 11.1-month median progression-free survival compared to just 7.1 months for the control arm. The confirmed objective response rate by blinded review reached a robust 60% for the 240mg group and 35% for the 160mg group. In contrast, the control arm managed a 33% confirmed objective response rate. ## Firmonertinib Safety and Tolerability Profile The FURVENT study revealed no new safety signals, and the safety profile aligned closely with previous clinical evaluations of firmonertinib. Grade 3 or higher treatment-emergent adverse events occurred in 52% of the 240mg cohort and 53% of the 160mg cohort. Both treatment groups experienced slightly fewer events than the control arm, which reported a 55% rate. Additionally, Grade 3 or higher treatment-related adverse events affected 26% of the 240mg group and 22% of the 160mg group. These figures represent a notable improvement over the 40% rate documented within the control arm. **AVBP Price Action:** ArriVent BioPharma shares were down 49.07% at $14.49 at the time of publication on Tuesday. The stock is trading at a new 52-week low, according to Benzinga Pro data. **Read Also: Tesla Rival Lucid Cuts Production Output by 38%, Misses Delivery Estimates Despite High Fuel Costs Leading to EV Surge** *Photo by Komsan Loonprom via Shutterstock* ### Related Stocks - [AVBP.US](https://longbridge.com/en/quote/AVBP.US.md) - [4568.JP](https://longbridge.com/en/quote/4568.JP.md) - [LCID.US](https://longbridge.com/en/quote/LCID.US.md) - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) ## Related News & Research - [ArriVent says Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC misses primary PFS endpoint](https://longbridge.com/en/news/301032671.md) - [ArriVent doses first patient in Phase 1 trial of ARR-002 dual-target ADC for ovarian, endometrial cancer](https://longbridge.com/en/news/301620875.md) - [ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)](https://longbridge.com/en/news/301079950.md) - [ASML Holding's Next Earnings Report on Oct. 14 Could Send the Stock Soaring. Here's Why.](https://longbridge.com/en/news/301605565.md) - [ArriVent Biopharma releases corporate presentation on late-stage oncology pipeline led by firmonertinib in EGFR-mutant NSCLC](https://longbridge.com/en/news/295707056.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**